Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Abdul Khairul Rizki Purba
Department of Health Science, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Cost-Effectiveness Analysis of Taxane-Based and Anthracycline-Based Chemotherapy in Stage 4 Breast Cancer Patients at Dr. Soetomo General Hospital, Surabaya, Indonesia Adele Sabrina; Abdul Khairul Rizki Purba; Azril Okta Ardhiansyah; Annette d’Arqom
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 17 No. 1 (2026): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/juxta.V17I12026.42-47

Abstract

Highlights: Epirubicin (anthracycline-based) showed the highest cost-effectiveness. Taxane-based regimens were less cost-effective compared with anthracyclines.   Abstract Introduction: Breast cancer, particularly stage 4, contributes significantly to global morbidity and mortality. Anthracycline- and taxane-based chemotherapies are commonly used for metastatic breast cancer, but their high costs necessitate a cost-effectiveness analysis to inform healthcare financing. This study aimed to assess the cost-effectiveness of these therapies for patients with stage 4 breast cancer at Dr. Soetomo General Hospital, Surabaya. Methods: A retrospective review of medical records from 124 stage 4 breast cancer patients treated in inpatient and outpatient settings was conducted. Effectiveness rates and cost data for epirubicin, doxorubicin, docetaxel, and paclitaxel were analyzed. Data processing involved basic calculations in Google Sheets, and the average cost-effectiveness ratio (ACER) and incremental cost-effectiveness ratio (ICER) were calculated. Ethical clearance was obtained. Results: Epirubicin was the most cost-effective, with an ACER of 958,878 Indonesian Rupiah (IDR) and an ICER of -IDR 2,603,667. Conclusion: Epirubicin is the most cost-effective chemotherapy option for stage 4 breast cancer, supporting its use in resource-limited settings and guiding cancer therapy decisions.
First Line and Second Line Anti-Tuberculosis Drugs Resistance Patterns in Drug Resistance Tuberculosis Patients at Dr. Soetomo General Academic Hospital Surabaya Period 2019-2022 R. Mochammad Naufal Affan Hakim; Abdul Khairul Rizki Purba; Tutik Kusmiati; Ni Made Mertaniasih
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 17 No. 2 (2026): IN-PROGRESS ISSUE (AUGUST 2026)
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/juxta.V17I22026.100-104

Abstract

Highlights: This study covers the prevalent pattern of first-line and second-line anti-TB drugs. High-dose INH was the most prevalent pattern among DR-TB patients.   Abstract Introduction: Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), with drug-resistant TB (DR-TB) posing a significant global health challenge. Drug-resistant TB is characterized by complex resistance patterns, leading to high morbidity and mortality rates. The lack of understanding regarding resistance to both primary and secondary anti-TB drugs contributed to the persistence of resistance. Methods: This was a retrospective, descriptive, observational study that used secondary data from the medical records of patients with DR-TB resistant to Rifampicin at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, from 2019 to 2022. A total of 199 patient samples were included, selected using the total sampling technique and based on specific inclusion and exclusion criteria. Data analysis was performed using Microsoft Excel software. Results: The most prevalent resistance pattern observed was high-dose Isoniazid (30.7%). A case of cross-resistance between Bedaquiline and Clofazimine was found in a single DR-TB patient. Among patients with a history of diabetes mellitus (DM), 41% of those with DM and 39.8% without DM showed high-dose Isoniazid (INH) resistance. One case of extensively drug-resistant TB occurred in a patient without DM. Conclusion: Drug-resistant TB remained a major health issue due to its high prevalence and complex treatment. Understanding resistance patterns and managing comorbidities, such as DM, was crucial for improving treatment outcomes.
Co-Authors Adele Sabrina Annette d’Arqom Azril Okta Ardhiansyah Kusmiati, Tutik Ni Made Mertaniasih R. Mochammad Naufal Affan Hakim